华讯
华讯
≡ 导航
网站首页
请拖入内容到容器
华讯
关于我们
请拖入内容到容器
华讯
Huawei and Verizon, patent litigation to reconciliation
Huawei and Verizon, patent litigation to reconciliation Huawei and Verizon Communications have agreed to settle two lawsuits alleging patent infringement, it was reported on July 12, Beijing time. Over the past 20 years, Huawei has reportedly conducted extensive cross-licensing negotiations with major patent holders in the telecom industry, and has signed more than 100 patent licensing agreements with major ICT manufacturers in the United States, Europe, Japan and South Korea. Together of the two separate cases, already in Texas last week trial. But late on Sunday local time, Huawei and Verizon filed joint motions in two US courts to dismiss both cases, as well as Verizon's counterclaim. In February 2020, Huawei sued Verizon, accusing the company of unauthorized use of more than a dozen Huawei patents in computer networks, download security, and video communications, seeking damages and royalties. In response to today's settlement, Huawei said in a statement: "We are pleased that the two companies have reached a settlement that ends their patent litigation. The terms of the agreement are confidential." People familiar with the matter said huawei's claims could exceed $1 billion. Huawei also noted that it has "more than 100,000 patents in force worldwide, including approximately 10,000 in the United States." Verizon has yet to comment, but said last year that the lawsuits were little more than a public relations stunt. In addition, Verizon has countersued Huawei for patent infringement. "We simply ask Verizon to respect Huawei's investment in research and development and either pay for the use of our patents or refrain from using them," Huawei said last year. Since 2015, huawei won the intellectual property rights of income accumulative total more than $1.4 billion, history accumulated more than 6 billion dollars to pay royalties for legitimate use other company's patent, with 80% paid to American companies. Only high investment can bring high return. The technology that leads the world is huawei's money. Billions and billions of research and development of a technology, with what provided free of charge to each other. So the royalty fees charged by huawei won't give up, how many patent verizon specific to huawei is unknown, but can be seen from the attitude of tough royalties huawei, technology is the absolute principle. With technology, we can promote the development of science and technology, and with technology, we are not afraid of intransigence. Huawei will insist on research and development, more technical breakthrough, form a larger system of patented technology.
Details 白箭头 黑箭头
华讯受邀出席2021第一届全国大学生芯片设计暑期学校开班仪式
7月12日,华讯受邀参加2021第一届全国大学生芯片设计暑期学校开班仪式。本次活动在示范性微电子学院产学融合发展联盟的指导下,由北京大学国家集成电路产教融合创新平台、东南大学微电子学院、南京集成电路培训基地主办,南京集成电路培训基地集成电路培训基地集成电路设计培训部、中科院微电子所南京智能技术研究院承办,同时,也获得了华讯、创意电子等多家企业的支持。 东南大学首席教授、南京集成电路培训基地主任时龙兴,江北新区研创园党工委副书记、南京集成电路培训基地书记周荣,北京大学微纳电子学研究院副院长贾嵩,东南大学电子科学与工程学院副院长徐申及相关企业代表参加,南京华讯知识产权顾问有限公司总经理侯庆辰先生也受邀参加本次活动。 活动上,各大高校老师对此次芯片暑期学校的开办发表了讲话:暑期学校是在国家战略下,通过地方政府、高校、企业等多方共同努力培养集成电路设计人才的一个体现。希望各位同学在暑期学校有所收获,在未来能够成为产业发展的中坚力量。 芯片设计人才是我国集成电路产业高质量发展的核心因素之一。IC设计产业的建设发展离不开优秀人才的支撑,南京集成电路培训基地举办首届全国大学生芯片设计暑期学校,邀请产学界的行业技术专家、高水平教授,围绕行业热点、智能芯片设计主题开展研讨课程、讲座、项目指导、行业精英面对面交流,将行业热点技术及真实项目相结合,以研讨课程与项目实践为手段,并安排芯片设计领域相关技术及工具的培训,主要培养创新型的IC设计人才。 华讯在芯片行业知识产权领域一直有着最专业知识和技能,为多家芯片企业的创新专利助力。此次芯片设计暑期学校的开办,华讯也会尽最大努力为学生提供帮助,为促进中国芯片产业发展出一份力。
Details 白箭头 黑箭头
Kerendia Receives FDA Approval for Slowing chronic kidney disease in Type 2 Diabetes
Kerendia Receives FDA Approval for Slowing chronic kidney disease in Type 2 Diabetes This month FDA announced that they have approved Kerendia (finerenone) tablets for the treatment of patients with chronic kidney disease associated with type 2 diabetes. Kerendia is indicated to delay chronic kidney disease progression. It is able to reduce the risk of kidney function decline, kidney failure, cardiovascular death, non-fatal heart attacks, and hospitalization for heart failure in adult diabetic patients. Now the drug has also been submitted for marketing authorization in China, European Union and other countries. There are 422 million people with diabetes, and there are up to 40% of all patients with type 2 diabetes develop chronic kidney disease. Diabetes is one of the most common causes of chronic kidney disease and kidney failure. Chronic kidney disease is the gradual loss of kidney function over a period of months to years. It occurs when the kidneys are damaged and cannot filter blood normally, and sometimes can progress to kidney failure. The patients are also at high risk of heart disease because of defective filtering. Kerendia is the first and only nonsteroidal mineralocorticoid receptor antagonist (MRA) for Type 2 diabetic patients with chronic kidney disease, compared to SGLT2 inhibitors, Farxiga (dapagliflozin) and Invokana (canagliflozin). It blocks overactivation of the mineralocorticoid receptor (MR) which contributes to fibrosis and inflammation. The drug is able to target fibrosis and inflammation to slow kidney disease progression. The efficacy of Kerendia was evaluated in a randomized, multicenter, double-blind, placebo-controlled in the phase III trial. There were 5,674 patients in the study. The study found that Kerendia beat placebo when it came to kidney function. That included fending off or slowing progression to kidney failure and kidney death. Furthermore, the study also found that Kerendia reduced the risk of cardiovascular death, non-fatal heart attack, and hospitalization for heart failure.   Kerendia received priority review and fast track designations for their application, and it will be commercially available in the U.S. by the end of July.   資料來源: https://www.fda.gov/drugs/drug-safety-and-availability/fda-approves-drug-reduce-risk-serious-kidney-and-heart-complications-adults-chronic-kidney-disease https://www.pharmalive.com/bayers-kerendia-receives-u-s-fda-approval/ https://finance.yahoo.com/news/bayers-kerendia-scores-long-awaited-111105329.html https://www.businesswire.com/news/home/20210709005441/en/Bayer%E2%80%99s-KERENDIA%C2%AE-finerenone-Receives-U.S.-FDA-Approval-for-Treatment-of-Patients-with-Chronic-Kidney-Disease-Associated-with-Type-2-Diabetes https://www.healio.com/news/endocrinology/20200710/finerenone-delays-diabetic-kidney-disease-progression-fideliodkd  
Details 白箭头 黑箭头
最新消息
请拖入内容到容器
重要服务
请拖入内容到容器
华讯
华讯
华讯

地址:江苏省南京市江北新区江淼路88号腾飞大厦B座20层2001

版权所有 © 南京华讯知识产权顾问有限公司      备案号:苏ICP备15002104号-1      网站建设:中企动力  南京      

联系我们
请拖入内容到容器
网站首页
关于我们
最新消息
重要服务
联系我们